BOOK BEFORE JULY 20
TO SAVE UP TO $800

14-16 November | Boston, MA, USA

www.neo-antigen.com

NeoAg Summit

Supercharging Personalized Neoantigen-based Cancer Immunotherapies



Maximizing Immunogenicity, Improving Scalable Manufacturing and Overcoming Regulatory Hurdles of Neoantigen Based Cancer Therapies

Expert Speakers Including:

Andrew Allen
Chief Excutive Officer
Gritstone Oncology

Richard Gaynor
President of R&D
Neon Therapeutics

Elisa Scarselli
Chief Scientific Officer
Nouscom AG

Laronna Colbert
Medical Officer, CBER
FDA

Christiane Niederlaeder
Senior Quality Assessor, MHRA (UK)
EMA

Fred Ramsdell
Vice President, Research
Parker Institute for Cancer Immunotherapy

Mette Husbyn
Chief Technical Officer
Vaccibody

Jessica Flechtner
Chief Scientific Officer
Genocea Biosciences

Drew Pardoll
Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins Medicine

Tel: +1 617 455 4188 **Mail:** info@hansonwade.com Neoantigens in Immunotherapy

hansonwade

Join the Exploding Neoantigen Community

The 3rd NeoAg Summit is the leading end-to-end industry-focused meeting dedicated to advancing neoantigen-based cancer vaccines and cell therapies.

The NeoAg Summit brings together pioneers personalizing immunotherapies to showcase the most up-to-date advances in **neoantigen prediction & validation**.

Boost the success of neoantigen targeting by truly **understanding complexities of the immune response**.

Gain clarity from the **FDA** & **EMA** on regulatory requirements in clinical development and CMC.

Move freely between **2 parallel tracks** focusing on **prediction & discovery; clinical development & manufacturing** to choose the talks most valuable for you and maximize your time out of the office.

Join leaders from **Neon Therapeutics, Gritstone Oncology, Moderna, Genentech** & **Parker Institute for Cancer Immunotherapy** as they share their approaches to overcoming key challenges and accelerating safe, effective and commercially viable neoantigen-based immunotherapies.

What Hanson Wade's attendees have said about our meetings

"This conference is a great way to get an overview of the current successes and challenges being faced by the field as a whole."
Trillium Therapeutics

"Well organized and good, broad selection of important topics covered."
Advaxis

Your Checklist to Advancing Neoantigen-Based Immunotherapies

1.
Evaluate neoantigen prediction approaches to fine tune clinical relevance.
Learn from computational methods of **Gritstone** and the **TESLA** consortium as well as the ATLAS bioassay method from Genocea

2.
Obtain a complete picture of the immune response to improve the efficacy of your therapy.
Let the leading immunology experts from **Immunicum** and the **Mayo Clinic** guide you through how to induce the right response



3.
Learn from case studies of past clinical trials to avoid any potential pitfalls.
Absorb the most advanced data from **Neon** and **Genentech**

4.
Navigate the regulatory landscape in the US and Europe for faster approval.
Representatives from the **FDA** and **EMA** will give perspectives on clinical development and manufacturing of personalized immunotherapy

5.
Streamline personalized manufacturing to minimize time and cost maximizing market access opportunities.
Get in depth knowledge on DNA and mRNA process development from **Vaccibody** and **Moderna**

Your Expert Speakers

Mark Findeis
Senior Director Research Biochemistry
Agenus

Dennis Underwood
Vice President of Molecular & Information Systems
Agenus

Stephen Johnston
Chief Executive Officer
Calviri

Eustache Paramithiotis
Vice President, Discovery
Caprion Biosciences

Christiane Niederlaender
Senior Quality Assessor, MHRA (UK)
EMA

William Watt
Chief Executive Officer
EpiThany

Laronna Colbert
Medical Officer, Office of Tissues & Advanced Therapies, CBER
FDA

Mahesh Yadav
Research & Early Development Scientist
Genentech

Jessica Flechtner
Chief Scientific Officer
Genocea Biosciences

Erin Jones
Global Head of Regulatory Affairs and Quality Assurance
Gritstone Oncology

Roman Yelensky
Chief Technology Officer
Gritstone Oncology

Andrew Allen
Chief Executive Officer
Gritstone Oncology

Rongfu Wang
Professor & Director of Center for Inflammation & Epigenetics
Houston Methodist

Alex Karlsson-Parra
Co-Founder & Chief Scientific Officer
Immunicum AB

Sune Justesen
Chief Scientific Officer
Immunitrack

Drew Pardoll
Director of Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins Medicine

Keith Knutson
Professor of Immunology
Mayo Clinic

David Pajerowski
Director, Process Development & CMC, Personalized Vaccines Unit
Moderna Therapeutics

Marc Wolfgang
Vice President of Technical Operations
Neon Therapeutics

Richard Gaynor
President of R&D
Neon Therapeutics

Jeff Roix
Chief Executive Officer
NeoPhore

Elisa Scarselli
Chief Scientific Officer
Nouscom AG

Trevor Clancy
Co-Founder & CSO
OncoImmunity

Alex Franzusoff
Chief Scientific Officer
PACT Pharma

Fred Ramsdell
Vice President of Research
Parker Institute for Cancer Immunotherapy

Antonella Vitiello
Founder & CEO
PersImmune

Sean Boyle
Director, Bioinformatics Applications
Personalis

Dennis Christensen
Head of Vaccine Adjuvant Research
Statens Serum Institute

Magnus Jaderberg
Chief Medical Officer
Targovax

Alena Gros
Group Leader
Tumor Immunology & Immunotherapy

Kaïdre Bendjama
Project Leader, Personalized Vaccines
Transgene SA

Rachel Marty
Bioinformatics Data Scientist
University of California, San Diego

Hideho Okada
Professor & Director of Brain Tumor Immunotherapy Program
University of California, San Francisco

Eli Gilboa
Professor
University of Miami

Mette Husbyn
Chief Technical Officer
Vaccibody

Michal Bassani-Sternberg
Director, Immunopeptidomics Unit,
UNIL/CHUV

Conference Day One | Thursday November 15 2018

8.00 Registration & Morning Refreshments

9.00 Chair's Opening Remarks

Andrew Allen
Chief Executive Officer
Gritstone Oncology

9.30 Public vs Private Neoantigens – Can Both Be Used Therapeutically?
- Therapeutics targeting public neoantigens can be "off-the-shelf" but patient selection is key – likely only a subset of solid tumors display these targets
- Most solid tumor patients could benefit from personalized immunotherapy against private neoantigens – neoantigen identification and product manufacturing are critical
- An ability to elicit profound T cell responses in humans is a likely obligate requirement of both approaches

Trevor Clancy
Co-Founder & CSO
OncoImmunity

10.00 An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens
- Here, we outline a high-performing machine learning approach, trained on massspectrometry data, that predicts naturally processed and presented antigens
- The predictor is integrated with several immune parameters, such as HLA binding, in a deep learning layer to predict bone fide neoantigens
- We illustrate its application to significantly improve the identification of neoantigen targets for personalized cancer immunotherapy

10.30 Speed Networking & Morning Refreshments

Prediction & Discovery

11.30 TESLA Consortium: Update on Neoantigen Predictions
- Over two dozen distinct computational pipelines exist for neoantigen prediction
- These pipelines utilize over a dozen different parameters to select peptides for vaccines
- The identity of the key factors in the selection of validated peptides are not clear
- Using 4 different bioassays, including patient-derived cells, the consortium is characterizing the key factors in peptide prediction

Fred Ramsdell, Vice President of Research, **Parker Institute for Cancer Immunotherapy**

12.00 Neoantigen Prediction: Approach and Validation
- Neoantigen identification for cancer immunotherapy remains a significant challenge
- Tumor immunopeptidomics combined with deep learning provides a powerful approach for neoantigen prediction
- Gritstone's EDGETM prediction model identifies therapeutically relevant neoantigens

Roman Yelensky, Chief Technology Officer, **Gritstone Oncology**

12.30 Immunitrack: a Unique Platform for Supporting Immuno-Oncology Projects
- NPrDx: a best-in-class peptide:MHC stability predictor, trained on proprietary peptide:MHC I & II stability assay data. The PrDx software can generate up to 80% less false-positives (compared to netMHC) with the identification of larger subsets of T-cell epitopes.
- Best-in-class peptide/MHC stability and affinity assays (US and European client contracts).
- Addresses the unmet client production need for customized MHC/epitope complexes and reagents

Sune Justesen, Chief Scientific Officer, **Immunitrack**

Clinical Development & Manufacturing

11.30 Neoantigen-targeting T Cell Therapy for Brain Cancer
- Overview of the neoantigen landscape for malignant gliomas
- Development of vaccine and T cell therapies targeting the novel H3.3K27M-derived neoantigen
- Unique challenges related to antigen heterogeneity of malignant gliomas

Hideho Okada, Professor & Director of UCSF Brain Tumor Immunotherapy Program, **University of California, San Francisco**

12.00 Heat Shock Protein Chaperoned Synthetic Peptide Cancer Vaccines
- Vaccine format: Heat shock protein noncovalently complexed peptides
- Use of the protein chaperone is dose sparing, reduces amount of antigenic peptide required
- Vaccine is adjuvanted with clinically validated QS-21

Mark Findeis, Senior Director Research Biochemistry, **Agenus**

12.30 Th1 Epitopes for Versatile Tumor- and Patient-tailored Vaccine Combination Therapies (VCT)
- EpiThany develops multiantigen cancer vaccines from a neo-repertoire of Th1-selective epitopes arising from overexpressed tumor antigens
- Multiple Phase 1 patient studies of our vaccines have demonstrated antigen-specific IFNg T cell titers comparable or superior to neo-epitope platforms, epitope spreading, and enhanced survival
- Retrospective analyses of archived epitopes for immune phenotype (Th1 or Th2) and a spectrum of genomic features suggests sequence homology to bacterial/fungal species may confer immunogenic properties

William Watt, Chief Executive Officer, **EpiThany**

13.00 Lunch & Networking

14.30 High-dimensional Mass Cytometry Epitope Mapping and Profiling of Neoantigen-specific T Cells in non-small Cell Lung Cancer Patients Treated with Atezolizumab.

- Mass cytometry and highly-multiplexed combinatorial peptide-MHC tetramer staining was used to longitudinally monitor neoantigen-specific CD8+ T cells in PBMC from 14 NSCL cancer patients treated with atezolizumab
- 782 candidate tumor neoantigens as well as 73 control peptides (mostly virus-derived epitopes) were screened across all patient samples
- T cell reactive for 13 different neoantigens were identified by unbiased analysis across all patients
- 9 out of 13 Neoantigen specific T cell responses were detected in patients with objective response (n=8) compared to only 4 hits in patients with progressive disease

Mahesh Yadav, Research & Early Development Scientist, **Genentech**

14.30 Personalized Adoptive NeoE-specific TCR-T Cell Therapies for Cancer

- Validation beyond Predictions: imPACTTM technology for the identification and isolation of neoE-specific T cells that constitute the intrinsic immune response in cancer patients
- Expanding the neoE specific T cell repertoire beyond HLA-A2
- Precision genome engineering of primary human T cells - PACT's non-viral technology for personalized neoE TCR engineering
- Functional characterization of personalized adoptive neoE-specific TCR-T cells – the path to clinical development

Alex Franzusoff, Chief Scientific Officer, **PACT Pharma**

15.00 Beyond Algorithms: The ATLAS Bioassay Method for Neoantigen Identification and Characterization

- HLA agnostic assay identifies CD4 and CD8 T cell neoantigens
- Uniquely distinguishes mutations that elicit stimulatory and inhibitory T cell responses
- Personalized neoantigen vaccine using ATLAS entering clinical development

Jessica Flechtner, Chief Scientific Officer, **Genocea Biosciences**

15.00 Personalized Adoptive T Cell Therapy Targeting MDS Stem Cell Neoantigens

- The need for neoantigen validation
- Do we know what fraction of potential neoantigens are recognized by T cells?
- Why adoptive transfer and not vaccination?

Antonella Vitiello, Founder & CEO, **PersImmune**

16.00 Afternoon Refreshments & Poster Session

Sean Boyle
Director, Bioinformatics Applications
Personalis

16.30 From Sample to Neoantigens for Vaccines: Key Challenges and Solutions

- cfDNA neoantigens: dealing with tumor heterogeneity
- Improving neoantigen identification
- Elaborating TME, immuno-modulators and vaccine response biomarkers
- Overcoming poor sample quality and quantity for NGS sequencing
- Overcoming sequencing gaps that can harbor neoantigens
- Validation and regulatory issues on the way to commercialization

Laronna Colbert
Medical Officer, Office of Tissues & Advanced Therapies, CBER
FDA

17.00 Clinical Considerations for Neoantigen-based Cancer Therapy - A Regulatory Perspective

- Current landscape of Neoantigen-based cancer therapies
- Challenges in clinical trial design
  - Study population
  - Target identification and selection
  - Safety and Efficacy Endpoints
- Opportunities to further advance the field

17.30 Chair's Closing remarks

"Great meeting with relevant and timely conduct! Good mix of scientific background and partner company information. Tightly coordinated agenda allowed for all speakers to participate."

Inovio Pharmaceuticals

Conference Day Two | Friday November 16 2018

9.15 Chair's Opening Remarks

Richard Gaynor
President of R&D
Neon Therapeutics

9.30 Neoantigen Approaches as Personal and Precision Cancer Therapeutics
- Neoantigens, vaccines and immune response

10.00 Morning Refreshments & Networking

Prediction & Discovery

10.30 Identification and Characterization of Presented Tumour Neo- Epitopes from Metastatic Colon Cancer
- Primary cancer data
- Metastatic cancer
- Normal tissue expression
- Functional characterisation

Eustache Paramithiotis, Vice President, Discovery, **Caprion Biosciences**

11.00 Presentation of MHC Bound Phophopeptides from Primary Patient Tissue Enables the Identification of Prevalent Molecular Targets for Vaccines and Cell Therapy
- Post-translational modification is central to the control of cellular pathways and are critical to a transformed cancerous state.
- The presentation of phosphopeptides on MHCs follows distinct allele preferences that reflect both the anchors required for strong MHC binding and motifs that mirror dysregulated kinases pathways. We will describe these.
- Identification of clear immune responses to phosphopeptides and not to unmodified peptides reflects the role of phosphorylation in breaking tolerance. Experiments showing immune responses in mouse experiments post vaccination will be described. In addition, highly specific TcRs to phosphopeptide MHC complexes will be described.

Dennis Underwood, Vice President of Molecular & Information Systems, **Agenus**

11.30 Identification of Tumor-resident and Circulating Neoantigen-specific Lymphoctyes
- OIdentification of neoantigen-specific lymphocytes from the tumor and peripheral blood
- Identification of neoantigens in patients with low mutation burden
- Comparison of techniques available for identification of personalized neoantigens

Alena Gros, Group Leader, **Tumor Immunology & Immunotherapy**

Clinical Development & Manufacturing

10.30 TG01 - A Neo-antigen Specific Peptide Vaccine Targeting RAS Mutations in Solid Tumors
- RAS mutations, a well characterised neo-antigen and therefore a most attractive target
- TG01, a 7 peptide vaccine able to cover 98% of RAS mutations in pancreas cancer
- Encouraging phase II clinical data using
- TG01 in combination with adjuvant chemotherapy in resected pancreas cancer

Magnus Jaderberg, Chief Medical Officer, **Targovax**

11.00 Vaccinating Against Neoantigens Induced in Concurrent and Future Tumors
- Experiments in advanced murine tumor models have shown that the approach was devoid of measurable toxicity, and was superior to vaccinating against "personalized" neoantigens
- Vaccinating against induced neoantigens overcomes the main limitations of targeting endogenous tumor neoantigens, generating clonal neoantigens, preventing immune evasion, and applicable to all patients (including the majority of patients that do not expressing endogenous neoantigens)

Eli Gilboa, Professor & Director of Dodson Interdisciplinary Immunotherapy Institute at Miller School of Medicine, **University of Miami**

11.30 Adjuvants for Peptide Based Cancer Vaccines – Are We There Yet?
- What are vaccine adjuvants – a general overview
- Why are adjuvants crucial for Neoantigen-based Cancer Vaccines
- What adjuvants does the cancer vaccine field use and are they good enough?

Dennis Christensen, Head of Vaccine Adjuvant Research, **Statens Serum Institute**

12.00 Lunch & Networking

13.00 Development and Testing of Cancer-type Specific Vaccines based on Frameshift Neoantigens
- Recurrent frameshift neoantigens are produced in tumors in RNA processing
- Immune reactions to the FS neoantigens can be detected by a simple blood assay
- Vaccines focused on particular cancer types can be pre-made from common FS neoantigens

Stephen Johnston, Chief Executive Officer, **Calviri**

13.00 Interrogating the Right Signals to Induce the Right Immune Response
- "Danger" signals, not "stranger" signals, as the main promoters of DC-mediated cross-priming of MHC class I restricted CD8+ T cells
- Allogeneic, off-the-shelf, "stranger"-stimulated DCs (alloDCs) promote efficient "danger"-mediated cross-priming of CD8+ T cells by endogenous "bystander" DCs
- The adenovector Ad5PTDf35 efficienty transduce alloDCs with with genes coding for tumor-specific antigens

Alex Karlsson-Parra, Co-Founder & Chief Scientific Officer, **Immunicum AB**

13.30 High Tumor Burden Mandates a Cancer Vaccine Targeting many Neoantigens

- Great Apes Ad (GAd) vaccination is highly effective as stand-alone treatment in an early therapeutic setting
- Large established tumors are resistant to cancer vaccination
- Resistance can be overcome by a vaccine targeting many neoantigens combined with immunomodulators

Elisa Scarselli, Chief Scientific Officer, **Nouscom AG**

13.30 Meeting the Neoantigen Vaccine Challenge with Virotherapeutics

- The place of neoantigen vaccines in the immunotherapeutic landscape
- Engineering improvements of viral vaccines for enhanced immunogenicity and efficacy
- Rethinking manufacturing paradigms to reduce lead time, cost and environmental impact of bespoke vaccines.

Kaïdre Bendjama, Project Leader, Personalized Vaccines, **Transgene SA**

14.00 A Novel Small-molecule Approach to induce De-novo Neoantigen Creation

- NeoPhore is creating drug inhibitors of DNA mismatch repair for cancer immunotherapy
- Mismatch repair is a highly validated target: genetic MMR deficiency generates neoantigens and checkpoint blockade sensitivity in both lab and clinical settings
- Mismatch repair inhibitors should exhibit efficacy across many cancer types, in combination with both checkpoint blockade and other immunostimulatory strategies

Jeff Roix, Chief Executive Officer, **NeoPhore**

14.00 Manufacturing, Regulatory and Logistics Challenges in the Rapidly Evolving Area of Individualized Therapeutic Cancer Vaccines: The Road to FASTdna at a low cost One-Stop-Shop

- Plasmid DNA vaccine
- Game changing regulatory environment
- Logistics

Mette Husbyn, Chief Technical Officer, **Vaccibody**

14.30 Mechanisms of Immune Suppression in the Tumor Microenvironment

- Understand the multiple mechanisms of immune suppression that are utilized by cancers to evade immune-mediate destruction
- Understand mechanisms underpinning the therapeutic efficacy of inhibitors of the PD-1/PD-L1 immune regulatory axis
- Understand emerging strategies to reverse local immune suppression in the tumor microenvironment

Keith Knutson, Professor of Immunology, **Mayo Clinic**

14.30 Strategic Management of COGs and Manufacturing Turnaround for Personalized Cancer Vaccine Development

- Setting targets
- Identifying and assessing opportunities
- Prioritizing improvement projects

Marc Wolfgang, Vice President of Technical Operations, **Neon Therapeutics**

15.00 Chair's Closing Remarks

15.15 Close of Summit

"The Neoantigen Summit is the focal point for updates in the cancer neoantigen vaccine field and should be attending by everybody with a keen interest in the field"

Vaccibody

Pre-Conference Workshop Day | Wednesday November 14, 2018

Workshop A

Maximizing the Chances of Immunogenicity of Neoantigen-Based Treatments to Improve Success Rates

9.00 - 12.00

Bioinformatics and mass spectroscopic predictions for epitope binding to MHC Class I has improved greatly. However, the immune response to selected neoantigens are still not well understood and can be determined easily.

In this workshop we discuss principles for the induction of effective neoantigen T cell responses.

Attendees will learn about:

- Why some epitopes are recognized and some are not?
- Is selecting for driver mutations the way to go?
- Reasoned approach to the selection of neoantigens
- The need to characterize the pre-existing T cell response to neoantigens in patients to be treated
- Are cross-reactive responses deleterious?

Workshop Leader
Antonella Vitiello
Founder & CEO
PersImmune

Dr. Antonella Vitiello founded PersImmune in 2010. Presently, PersImmune is conducting a clinical trial (NCT03258359) of personalized adoptive T cell therapy targeting MDS stem cell neoantigens (PACTN).

Workshop Leader
Rachel Marty
Bioinformatics Data Scientist
University of California, San Diego

Rachel Marty's research focuses on algorithmic classification of genomic, immune-coding regions that impact cancer progression.

Workshop B

Neoantigen Selection, Prediction and Validation to Improve Target Efficacy

13.00 - 16.00

Identification of tumor antigens and neoantigens is critical to the success of immune targeting in next generation cancer vaccines and cell immunotherapies. A variety of methods are being employed to approach neoantigen calling.

In this workshop we explore the landscape of techniques and technologies in the development of neoantigen-based therapies.

Attendees will learn about:

- Optimal process for neoantigen selection
- Case studies for various methods for identification and validation of neoantigen
- Approaches that are less costly and time consuming
- Immune dominance of neoantigens and dual recognition of neoantigens by a single T cell receptor

Workshop Leader
Rongfu Wang
Professor & Director of Center for Inflammation & Epigenetics
Houston Methodist

Professor Rongfu Wang currently serves as the Director of the Center for Inflammation and Epigenetics and Professor of Microbiology and Immunology, Weill Cornell Medicine, Cornell University.

Workshop Leader
Michal Bassani-Sternberg
Director, Immunopeptidomics Unit, Department of Oncology
UNIL/CHUV

Michal Bassani-Sternberg integrates mass spectrometry based immunopeptidomics into the innovative translational clinical strategy of personalized immunotherapy.

Neoantigen Manufacturing & Regulations Bootcamp

Optimizing Manufacturing & Quality of Personalized Therapies from Regulatory & Technical Perspectives

9.00 - 16.00

Neoantigen based vaccines and cell therapies have made significant progress and as commercialization draws closer, limitations in personalised manufacturing process is causing the effective therapies to be expensive and time consuming to produce. This bootcamp brings together quality, regulatory and process development perspectives to give you a comprehensive boost in your CMC approaches.

Attendees will learn about:

- Understanding Regulatory Requirements and Cutting Time and Cost of Manufacturing
- Experiences and perspectives in working with FDA & EMA
- Regulatory and Compliance Considerations in the Manufacture of Individualized Medicines
- Approaches to release tests that cut time and cost
- Optimizing process development

Workshop Leader
Erin Jones
Senior Vice President and Global Head of Regulatory Affairs and Quality Assurance
Gritstone Oncology

Erin Jones is senior vice president and global head of regulatory affairs and quality assurance at Gritstone Oncology. Previously, he oversaw BLA submissions and ODAC preparations for Nerlynx™, Kadcyla™ and Perjeta™ in HER2-positive breast cancer, and approvals for Herceptin™ in breast and gastric cancers. He has directed regulatory development of dozens of small molecules, monoclonal antibodies, antibody-drug conjugates, plasmids, adenoviral gene therapies, and companion diagnostics in oncology and hematology at Genentech, BioMarin, Cephalon and Centocor. He received his M.S. in computer systems at Pennsylvania State University.

Workshop Leader
Christiane Niederlaender
Senior Quality Assessor, MHRA (UK)
EMA

Christiane Niederlaender is a Senior Quality Assessor and Deputy Unit Manager of the Biologicals Unit of the MHRA Licensing Division, where she has worked since 2011. She has experience in all classes of biological medicinal products, but her work has a particular focus on advanced therapy medicinal products. She is the UK representative at EMA CAT. Prior to joining the MHRA, Christiane worked for the UK Human Tissue Authority and has extensive regulatory and scientific experience with in tissue and cell therapies.

Christiane received a Ph.D. in molecular developmental neurobiology from Kings College London and has spent several years researching and publishing in the area of cancer, development and neurobiology before taking a law degree and joining the regulatory profession.

Workshop Leader
David Pajerowski
Director, Process Development & CMC, Personalized Vaccines Unit
Moderna Therapeutics

David Pajerowski is Director of Process Development and CMC for Moderna's Personalized Vaccines Unit. Previously, he was Associate Director of PD and Tech Transfer at WuXi AppTec in Philadelphia, where he focused on the manufacturing readiness of cell therapy and AAV processes. Prior to 2014, Dave held multiple roles within MS&T and PD at Merck and Company in West Point, PA. His experience spans from early development to commercial support of licensed vaccine products, and crosses cell culture and purification of mRNA, VLP and live virus vaccines, gene therapy vectors, and cell therapies. Dave holds a Doctorate in Biological Engineering from the University of Pennsylvania, and obtained his Bachelors of Chemical Engineering from the University of Delaware.

PARTNERS

Industry Development Partner

OncoImmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in clinically actionable time-frame.

www.oncoimmunity.com

Expertise Partner

Personalis, Inc. provides genomic solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Our patented ACE Technology improves every step in the sequencing process, from nucleic acid extraction, to sequencing, to data analytics. This delivers augmented coverage of difficult-to-sequence genomic regions that are missed with conventional sequencing techniques. This comprehensive approach provides data of the highest quality to enable the rational design and development of effective cancer immunotherapies.

www.personalis.com

Program Partner

Caprion Biosciences, a CRO laboratory, helps advance biomarker research through scientific partnership and innovative technologies. Our platforms include large-scale proteomic profiling using quantitative mass spectrometry, multi-parametric flow cytometry (peripheral blood and TILs), cytokine testing and ELISpot for monitoring of complex innate and adaptive immune responses. Through a unique approach, we provide discovery and characterization of tumor antigens and neo-epitopes. Our team of expert draws on deep understanding and years of experience in immuno-oncology and immunology.

www.caprion.com

Program Partner

Immunitrack is a spin-out from the academic group that created netMHC. PrdX is a novel peptide MHC stability predictor based on data from our best in class MHC I and II peptide stability assays. Compared to netMHC, PrdX identifies less false positives and is far more specific in identification of potential T cell epitopes. Apart from PrdX we offer in-vitro peptide MHC affinity and stability measurements as well as tetramers. Our platform could support most IO project.

www.immunitrack.com

Exhibitor

Almac has been supplying peptides to the research community and for clinical trials for over 20 years. The field of personalized cancer vaccines requires a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a unique offering to meet all of those demands, which can be tailored to meet specific client needs.

www.almacgroup.com/api-chemical-development

Exhibitor

Bachem provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. The group has a global reach with more experience and know-how than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership. Bachem. Pioneering Partner for Peptides

www.bachem.com

BECOME A PARTNER

Jennifer MacKay
Partnerships Director
T: +1 617 455 4188
E: sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.neo-antigen.com/register

Tel: +1 212 537 5898

Email: register@hansonwade.com

1. Transform your Neoantigen calling strategy and generate the right immune response
2. Optimize personalized manufacturing processes and techniques to cut time and cost to maximize market access
3. Get a comprehensive global regulatory perspective from the FDA and EMA for faster approval

Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Contact: register@hansonwade.com

SECURE YOUR PLACE

Industry Pricing *	Register & Pay By Friday July 20	Standard Prices
Conference + Bootcamp	$3297 **(save $800)**	$3897 **(save $200)**
Conference + 2 Workshops (A & B)	$3297 **(save $800)**	$3897 **(save $200)**
Conference + 1 Workshop (A or B)	$2698 **(save $700)**	$3298 **(save $100)**
Conference Only	$2099 **(save $600)**	$2699
Workshops (Each)	$699	

Standard Pricing	Register & Pay By Friday July 20	Standard Prices
Conference + Bootcamp	$3697 **(save $800)**	$4297 **(save $200)**
Conference + 2 Workshops (A & B)	$3697 **(save $800)**	$4297 **(save $200)**
Conference + 1 Workshop (A or B)	$3098 **(save $700)**	$3698 **(save $100)**
Conference Only	$2499 **(save $600)**	$3099
Workshops (Each)	$699	

Academic Pricing	Register & Pay By Friday July 20	Standard Prices
Conference + Bootcamp	$2097 **(save $500)**	$2397 **(save $200)**
Conference + 2 Workshops (A & B)	$2097 **(save $500)**	$2397 **(save $200)**
Conference + 1 Workshop (A or B)	$1698 **(save $400)**	$1998 **(save $100)**
Conference Only	$1299 **(save $300)**	$1599
Workshops (Each)	$499	

***Pharma and biotech companies currently and publically developing neoantigen based drugs for therapeutic use.**





VENUE

Hyatt Regency Cambridge, MA
Address: 575 Memorial Dr.
Cambridge, Massachusetts, USA, 02139-4896

For further information or assistance, please visit https://www.hyatt.com/en-US/hotel/massachusetts/hyatt-regency-cambridge-overlooking-boston/bosrc

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Code: 8149